html

Ahammune Biosciences Raises $5 Million for Immune-Mediated Skin Disease Treatment

Ahammune Biosciences, a clinical-stage therapeutics company specializing in developing novel treatments for immune-mediated skin diseases, has successfully secured USD 5 million in Series A funding. This funding round was spearheaded by pi Ventures, with participation from prominent investors including Capital2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, and existing investors like Ideaspring Capital, Kotak Alternate Assets, Legacy Assets LLP, and IAN.

Utilizing the Funding for Advancement

The newly acquired funds will be strategically allocated to support the advancement of Ahammune's drug candidate, designed to effectively treat vitiligo, a chronic skin condition characterized by the appearance of white patches.

• The funding will facilitate Phase II human clinical trials for the drug candidate.
• It will also support the expansion of the company's patent portfolio.
• Furthermore, it will enable the acceleration of research into other immune-related skin diseases.

Ahammune's Approach to Immune-Mediated Skin Diseases

Founded in 2016 by Dr. Parul Ganju and Dr. Krishnamurthy Natarajan, Ahammune is dedicated to finding innovative solutions for chronic skin conditions. Dr. Ganju, the CEO, emphasizes the unique approach of their drug candidate, stating that it "does not cause generalized immunosuppression. It not only stops the spread of white patches but also helps restore skin color."

Investor Confidence in Ahammune's Potential

Roopan Aulakh, Managing Director of pi Ventures, expresses confidence in Ahammune's potential, stating, "Their breakthrough drug molecule could treat vitiligo without the side effects seen in current treatments. We are excited to support them in this important journey."

Previous Funding Rounds

In 2021, Ahammune secured an undisclosed funding in a round led by Ideaspring Capital and Indian Angel Network, with participation from Kotak Private Equity, Dr. Ajith Kamath, Legacy Assets LLP, along with Dr. Anand Deshpande and Suman Kant Munjal.

Conclusion

This significant Series A funding underscores the strong belief in Ahammune's potential to revolutionize the treatment of immune-mediated skin diseases, particularly vitiligo. The company's focus on developing a drug candidate that addresses the limitations of current treatments holds promise for improving the lives of millions affected by these chronic skin conditions.